

Publisher Correction: A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells

<https://doi.org/10.1038/s41586-022-04652-x>

Published online: 24 March 2022

Correction to: *Nature* <https://doi.org/10.1038/s41586-022-04439-0>

Published online 23 February 2022



Check for updates

**Edward Seung, Zhen Xing, Lan Wu, Ercole Rao,
Virna Cortez-Retamozo, Beatriz Ospina, Liqing Chen, Christian Beil,
Zhili Song, Bailin Zhang, Mikhail Levit, Gejing Deng, Andrew Hebert,
Patrick Kirby, Aiqun Li, Emma-Jane Poulton, Rita Vicente,
Audrey Garrigou, Peter Piepenhagen, Greg Ulinski,
Michele Sanicola-Nadel, Dinesh S. Bangari, Huawei Qiu, Lily Pao,
Dmitri Wiederschain, Ronnie Wei, Zhi-yong Yang & Gary J. Nabel**

In the version of this article initially published, there were labeling errors in Fig. 1a. In the top-left, bright green “Anti-HER2” section, the top peptide node now labeled “VH-3” initially appeared as “VL-3.” In the top-middle blue “Anti-CD3” section, the lower node now labeled “VH-2” initially appeared as “VL-2.” In the top-right olive “Anti-CD28” section, the top node now labeled “VH-1” and the lower node now labeled “VL-1” initially appeared as “VL-1” and “VL-3,” respectively. The changes have been made to the HTML and PDF versions of the article.

© The Author(s), under exclusive licence to Springer Nature Limited 2022